HighTower Advisors
INBX icon

HighTower Advisors’s Inhibrx INBX Stock Holding History

HighTower Advisors’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$58.5M Sell
870,200
-307
-0% -$22.8K 0.06% 318
2025
Q4 		$68.8M Sell
870,507
-1,252
-0.1% -$85.3K 0.08% 260
2025
Q3 		$29.4M Hold
871,759
– – 0.03% 489
2025
Q2 		$12.4M Buy
871,759
+5
+0% +$65 0.02% 719
2025
Q1 		$12.2M Buy
871,754
+90,002
+12% +$1.22M 0.02% 693
2024
Q4 		$12M Buy
781,752
+659,252
+538% +$10M 0.02% 678
2024
Q3 		$1.92M Buy
122,500
+15,000
+14% +$211K ﹤0.01% 1545
2024
Q2 		$1.52M Buy
+107,500
New +$1.68M ﹤0.01% 1601

Other funds holding INBX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

HighTower Advisors's INBX Position: Q1 2026 in Review

HighTower Advisors reduced its Inhibrx (INBX) stake by 0.04% in Q1 2026, selling an estimated $22.8K and leaving 870,200 shares worth $58.5M. The position accounts for 0.06% of the portfolio, ranked #318.

HighTower Advisors first reported a position in INBX in Q2 2024 and has held it in 8 quarters since. The position peaked at $68.8M in Q4 2025. 135 funds tracked by Wall St. Rank hold INBX as of Q1 2026.

  • HighTower Advisors held 870,200 shares of Inhibrx worth $58.5M as of Q1 2026.
  • HighTower Advisors sold 307 Inhibrx shares in Q1 2026, an estimated $22.8K.
  • Inhibrx made up 0.06% of HighTower Advisors's portfolio in Q1 2026, its #318 holding.
  • HighTower Advisors first reported a position in Inhibrx in Q2 2024 and has held it in 8 quarters since.
  • HighTower Advisors's Inhibrx position peaked at $68.8M in Q4 2025.
  • 135 funds tracked by Wall St. Rank held Inhibrx as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.